Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toshihiko Doi

Showing results (21-30 of 247) with videos related to

Pageof 25
Sort By:
Japanese Journal of Clinical Oncology|January 17, 2016
Bevacizumab safety in Japanese patients with colorectal cancerKiyohiko Hatake, Toshihiko Doi, Hiroyuki Uetake, et al.
Cancer Science|October 24, 2017
Phase I study of single-agent ribociclib in Japanese patients with advanced solid tumorsToshihiko Doi, Becker Hewes, Tomoyuki Kakizume, et al.
Investigational New Drugs|October 2, 2017
Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumorsTomohiro Nishina, Shunji Takahashi, Ryota Iwasawa, et al.
Investigational New Drugs|January 8, 2020
Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignanciesToshihiko Doi, Narikazu Boku, Yusuke Onozawa, et al.
Japanese Journal of Clinical Oncology|February 13, 2009
Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in JapanNaomi Kiyota, Makoto Tahara, Shigenori Kadowaki, et al.
Investigational New Drugs|December 11, 2019
Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumorsToshihiko Doi, Nobuaki Matsubara, Akira Kawai, et al.
Oncology Reports|December 6, 2005
Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancerTomonori Yano, Toshihiko Doi, Atsushi Ohtsu, et al.
Japanese Journal of Clinical Oncology|June 6, 2017
A Phase 1 study evaluating AMG 337 in Asian patients with advanced solid tumorsHirofumi Yasui, Ning Go, Hui Yang, et al.
Investigational New Drugs|September 17, 2020
A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumorsToshihiko Doi, Masaomi Tajimi, Joji Mori, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 15, 2014
Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinomaAkiko Kawano Nagatsuma, Masaki Aizawa, Takeshi Kuwata, et al.
Pageof 25

Showing results (21-30 of 247) with videos related to

Sort By:
Pageof 25
Japanese Journal of Clinical Oncology|January 17, 2016
Bevacizumab safety in Japanese patients with colorectal cancerKiyohiko Hatake, Toshihiko Doi, Hiroyuki Uetake, et al.
Cancer Science|October 24, 2017
Phase I study of single-agent ribociclib in Japanese patients with advanced solid tumorsToshihiko Doi, Becker Hewes, Tomoyuki Kakizume, et al.
Investigational New Drugs|October 2, 2017
Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumorsTomohiro Nishina, Shunji Takahashi, Ryota Iwasawa, et al.
Investigational New Drugs|January 8, 2020
Phase I dose-escalation study of the safety, tolerability, and pharmacokinetics of aflibercept in combination with S-1 in Japanese patients with advanced solid malignanciesToshihiko Doi, Narikazu Boku, Yusuke Onozawa, et al.
Japanese Journal of Clinical Oncology|February 13, 2009
Systemic chemotherapy with cisplatin plus 5-FU (PF) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): efficacy and safety of a lower dose of PF (80/800) at a single institution in JapanNaomi Kiyota, Makoto Tahara, Shigenori Kadowaki, et al.
Investigational New Drugs|December 11, 2019
Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumorsToshihiko Doi, Nobuaki Matsubara, Akira Kawai, et al.
Oncology Reports|December 6, 2005
Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancerTomonori Yano, Toshihiko Doi, Atsushi Ohtsu, et al.
Japanese Journal of Clinical Oncology|June 6, 2017
A Phase 1 study evaluating AMG 337 in Asian patients with advanced solid tumorsHirofumi Yasui, Ning Go, Hui Yang, et al.
Investigational New Drugs|September 17, 2020
A phase 1 study of crenigacestat (LY3039478), the Notch inhibitor, in Japanese patients with advanced solid tumorsToshihiko Doi, Masaomi Tajimi, Joji Mori, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 15, 2014
Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinomaAkiko Kawano Nagatsuma, Masaki Aizawa, Takeshi Kuwata, et al.
Pageof 25